Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 10/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18613113 | 1.00 | DHODH (0.66) | DHODHL3MBTL1ALDH1A1MEN1KMT2A | |
| SCHEMBL5969916 | 0.87 | EPHX2 (0.51) | DHODHL3MBTL1ALDH1A1MEN1KMT2A | |
| SCHEMBL29551628 | 0.85 | HTT (0.59) | ALDH1A1MEN1KMT2AHTT | |
| SCHEMBL5714269 | 0.85 | HTT (0.59) | ALDH1A1MEN1KMT2AHTT | |
| SCHEMBL18761357 | 0.85 | HTT (0.59) | ALDH1A1MEN1KMT2AHTT | |
| SCHEMBL24804264 | 0.83 | EPHX2 (0.60) | DHODHL3MBTL1ALDH1A1MEN1KMT2A | |
| SCHEMBL2463602 | 0.82 | TAOK1 (0.55) | ALDH1A1 | |
| SCHEMBL26999632 | 0.80 | EPHX1 (0.57) | ALDH1A1MEN1KMT2AHTT | |
| SCHEMBL2406505 | 0.79 | ALDH1A1 (0.76) | DHODHL3MBTL1ALDH1A1MEN1KMT2A | |
| SCHEMBL1565743 | 0.79 | ALDH1A1 (0.76) | DHODHL3MBTL1ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220016106-A1 | COMPOUNDS AND METHODS USEFUL FOR TREATING OR PREVENTING HEMATOLOGICAL CANCERS | THE BROAD INSTITUTE, INC. (US) | 2022-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220016106-A1 | COMPOUNDS AND METHODS USEFUL FOR TREATING OR PREVENTING HEMATOLOGICAL CANCERS | DHODH, MCL1, DHX15 | DHODH 1/4885L3MBTL1 667/4885ALDH1A1 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.